XML 39 R24.htm IDEA: XBRL DOCUMENT v3.22.1

REVENUES (Tables)

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenues

The following table summarizes our Total revenues:

						Three Months Ended March 31, 2022																								Three Months Ended March 31, 2021
(in millions)						U.S.						Europe						Other International						Total						U.S.						Europe						Other International						Total
Product sales:
HIV
Biktarvy						$	1,706					$	261					$	184					$	2,151					$	1,465					$	216					$	143					$	1,824
Complera/Eviplera						17						24						4						44						25						34						4						63
Descovy						311						32						31						374						282						42						35						359
Genvoya						457						77						48						582						506						106						61						673
Odefsey						232						96						11						339						240						113						14						367
Stribild						22						8						3						32						31						11						4						46
Truvada						28						4						6						38						119						7						9						135
Revenue share - Symtuza(1)						86						44						3						132						89						44						2						135
Other HIV(2)						5						4						5						14						29						5						14						48
Total HIV						2,862						550						295						3,707						2,786						578						286						3,650
Veklury						801						304						430						1,535						820						388						248						1,456
Hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3)						13						4						18						35						19						16						21						56
Sofosbuvir/Velpatasvir(4)						162						83						85						330						214						75						92						381
Other HCV(5)						24						8						2						34						25						44						4						73
Total HCV						199						95						105						399						258						135						117						510
Hepatitis B virus (“HBV”) / Hepatitis delta virus (“HDV”)
Vemlidy						80						9						111						200						77						8						96						181
Viread						—						6						17						23						4						7						20						31
Other HBV/HDV(6)						—						13						—						13						—						8						—						8
Total HBV/HDV						80						28						128						235						81						23						116						220
Cell therapy
Tecartus						47						15						1						63						27						4						—						31
Yescarta						125						77						9						211						92						61						7						160
Total cell therapy						172						92						10						274						119						65						7						191
Trodelvy						119						25						2						146						72						—						—						72
Other
AmBisome						25						66						53						144						12						66						43						121
Letairis						43						—						—						43						54						—						—						54
Other(7)						26						15						9						50						38						20						8						66
Total other						94						81						62						236						104						86						51						241
Total product sales						4,329						1,174						1,031						6,534						4,240						1,275						825						6,340
Royalty, contract and other revenues						27						27						3						56						20						61						2						83
Total revenues						$	4,355					$	1,202					$	1,033					$	6,590					$	4,260					$	1,336					$	827					$	6,423

_______________________________

(1)     Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).

(2)     Includes Atripla, Emtriva and Tybost.

(3)     Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4)     Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5)     Includes Vosevi and Sovaldi.

(6)     Includes Hepcludex and Hepsera.

(7)     Includes Cayston, Jyseleca, Ranexa and Zydelig.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:

						Three Months Ended
						March 31,
(as a percentage of total revenues)						2022						2021
AmerisourceBergen Corporation						19		%				27		%
Cardinal Health, Inc.						23		%				18		%
McKesson Corporation						20		%				17		%

Revenues Recognized from Performance Obligations Satisfied in Prior Periods

The following table summarizes revenues recognized from performance obligations satisfied in prior periods:

						Three Months Ended
						March 31,
(in millions)						2022						2021
Revenue share with Janssen and royalties for licenses of intellectual property						$	184					$	226
Changes in estimates						$	230					$	332

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of expected timing for satisfying remaining performance obligation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration